文献速递细菌感染、耐药与抗菌药物

优化达巴万星治疗复杂性MRSA感染的给药方案:多中心群体药代动力学研究

Optimizing dalbavancin dosing for complicated methicillin-resistant Staphylococcus aureus infections: a multicentre population pharmacokinetic study.
PubMed 文献 · Clin Microbiol Infect · 2026-06-08

该多中心队列研究纳入311例接受达巴万星治疗的成人MRSA感染患者,采用群体药代动力学建模与蒙特卡洛模拟评估延长疗程的给药策略。结果显示肥胖患者清除率增加49%、外周分布容积增加81%,标准标签方案在肥胖患者中4周靶标达成率仅50-60%,基于体重指数和肾功能的双剂或三剂策略在93%蛋白结合假设下可达≥90%靶标达成率。

要点

  • 肥胖患者达巴万星清除率增加49%、外周分布容积增加81%,标准方案暴露不足。
  • 标准标签方案在肥胖患者中4周靶标达成率仅50-60%,eGFR≥120 mL/min者最低。
  • 基于BMI和eGFR的双剂或三剂策略在93%蛋白结合假设下靶标达成率≥90%。

核心结论

  • 体重、肾功能和蛋白结合假设实质性影响延长达巴万星治疗的靶标达成率,模拟指导的方案提供实用门诊框架但高蛋白结合假设需谨慎解读。

研究设计与样本

  • 多中心队列研究,纳入5个中心311例接受达巴万星治疗的成人MRSA感染患者,共946个血药浓度,随访超过8周。
  • 采用非线性混合效应法进行群体药代动力学建模,评估体型和肾功能协变量,蒙特卡洛模拟每场景n=1000。

主要发现

  • 肥胖患者(n=64)较正常体重患者清除率高49%、外周分布容积高81%。
  • 标准标签方案在肥胖患者中4周靶标达成率仅50-60%,eGFR≥120 mL/min者最低。
  • 基于BMI和eGFR的双剂和三剂策略在93%蛋白结合假设下靶标达成率≥90%。
  • 敏感性分析显示靶标达成率在93-96%蛋白结合时基本保持,但在97-99%时下降,尤其肥胖、eGFR≥120 mL/min、低剂量周方案和隔周给药时。

关键数值与推荐

  • 目标为维持达巴万星浓度≥8.04 mg/L至4周。
  • 标准标签方案在肥胖患者中4周靶标达成率仅50-60%。
  • 基于BMI和eGFR的双剂和三剂策略在93%蛋白结合假设下靶标达成率≥90%。

临床怎么用

  • 对肥胖或肾功能亢进(eGFR≥120 mL/min)的MRSA感染患者,标准达巴万星方案可能暴露不足,应考虑基于BMI和eGFR的延长疗程方案。
  • 蛋白结合假设影响靶标达成率,高蛋白结合状态(97-99%)下需个体化评估,尤其高危患者。

局限性

  • 蛋白结合敏感性分析范围93-99%,高蛋白结合假设下靶标达成率下降,结果需谨慎解读。
  • 本研究为观察性队列结合模拟,需临床结局数据验证模拟指导方案的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Dalbavancin is increasingly used off-label for complicated methicillin-resistant Staphylococcus aureus infections requiring prolonged antimicrobial exposure. However, approved dosing regimens were developed for short-course therapy and may provide inadequate exposure in patients with obesity or preserved kidney function. We aimed to develop a practical dosing strategy for prolonged dalbavancin therapy using population pharmacokinetic modelling and simulation. METHODS: We conducted a multicentre cohort study of adults treated with dalbavancin for presumed or documented methicillin-resistant Staphylococcus aureus infections across five centres. Dalbavancin plasma concentrations were measured using a validated liquid chromatography- tandem mass spectrometry (LC-MS/MS) assay. Population pharmacokinetic modelling was performed using nonlinear mixed-effects methods with evaluation of body size and kidney function covariates. Monte Carlo simulations (n = 1000 per scenario) estimated the probability of target attainment (PTA) for maintaining dalbavancin concentrations ≥8.04 mg/L through 4 weeks across body mass index and estimated glomerular filtration rate (eGFR) strata. Candidate regimens for 4-8 weeks of coverage were evaluated, with protein-binding sensitivity analyses across 93-99%. RESULTS: A total of 311 patients contributed 946 dalbavancin concentrations with follow-up extending beyond 8 weeks. Compared with normal-weight patients, those with obesity (n = 64) exhibited 49% higher clearance and 81% higher peripheral volume of distribution. Standard labelled regimens achieved 4-week PTA in only 50-60% of obese patients, with the lowest attainment observed among those with eGFR ≥120 mL/min. body mass index- and eGFR-informed two- and three-dose strategies achieved ≥90% PTA under the 93% protein-binding assumption. Sensitivity analyses showed that PTA was generally preserved at 93-96% protein binding but declined at 97-99%, particularly with obesity, eGFR ≥120 mL/min, lower-dose weekly regimens, and every-other-week dosing. CONCLUSIONS: Body size, kidney function, and protein-binding assumptions materially influence dalbavancin PTA during prolonged therapy. Simulation-informed regimens provide a practical outpatient framework, but higher protein-binding assumptions support cautious interpretation and consideration of individualized assessment in high-risk patients.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Pai MP, Cojutti PG, De Paola R, et al. Optimizing dalbavancin dosing for complicated methicillin-resistant Staphylococcus aureus infections: a multicentre population pharmacokinetic study. Clin Microbiol Infect. 2026. PMID: 42264180. doi:10.1016/j.cmi.2026.05.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。